Politou M - Search Results

1

Human invariant NKT cells are required for effective in vitro alloresponses.

Patterson S, Kotsianidis I, Almeida A, Politou M, Rahemtulla A, Matthew B, Schmidt RR, Cerundolo V, Roberts IA, Karadimitris A. Patterson S, et al. Among authors: politou m. J Immunol. 2005 Oct 15;175(8):5087-94. doi: 10.4049/jimmunol.175.8.5087. J Immunol. 2005. PMID: 16210612

2

Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration.

Terpos E, Politou M, Rahemtulla A. Terpos E, et al. Among authors: politou m. J Cancer Res Clin Oncol. 2004 Oct;130(10):623-5. doi: 10.1007/s00432-004-0593-4. Epub 2004 Jul 28. J Cancer Res Clin Oncol. 2004. PMID: 15449188

3

New insights into the pathophysiology and management of bone disease in multiple myeloma.

Terpos E, Politou M, Rahemtulla A. Terpos E, et al. Among authors: politou m. Br J Haematol. 2003 Dec;123(5):758-69. doi: 10.1046/j.1365-2141.2003.04712.x. Br J Haematol. 2003. PMID: 14632767 Free article. Review. No abstract available.

4

The role of markers of bone remodeling in multiple myeloma.

Terpos E, Politou M, Rahemtulla A. Terpos E, et al. Among authors: politou m. Blood Rev. 2005 May;19(3):125-42. doi: 10.1016/j.blre.2004.06.001. Blood Rev. 2005. PMID: 15748961 Review.

5

Anti-angiogenic effect of bortezomib in patients with multiple myeloma.

Politou M, Naresh K, Terpos E, Crawley D, Lampert I, Apperley JF, Rahemtulla A. Politou M, et al. Acta Haematol. 2005;114(3):170-3. doi: 10.1159/000087894. Acta Haematol. 2005. PMID: 16227683 No abstract available.

6

Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma.

Terpos E, Politou M, Szydlo R, Goldman JM, Apperley JF, Rahemtulla A. Terpos E, et al. Among authors: politou m. Br J Haematol. 2003 Oct;123(1):106-9. doi: 10.1046/j.1365-2141.2003.04561.x. Br J Haematol. 2003. PMID: 14510950 Free article.

7

Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma.

Terpos E, Politou M, Viniou N, Rahemtulla A. Terpos E, et al. Among authors: politou m. Leuk Lymphoma. 2005 Dec;46(12):1699-707. doi: 10.1080/10428190500175049. Leuk Lymphoma. 2005. PMID: 16263571 Review.

8

Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS).

Politou M, Terpos E, Anagnostopoulos A, Szydlo R, Laffan M, Layton M, Apperley JF, Dimopoulos MA, Rahemtulla A. Politou M, et al. Br J Haematol. 2004 Sep;126(5):686-9. doi: 10.1111/j.1365-2141.2004.05092.x. Br J Haematol. 2004. PMID: 15327520 Free article.

9

Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation.

Politou MC, Heath DJ, Rahemtulla A, Szydlo R, Anagnostopoulos A, Dimopoulos MA, Croucher PI, Terpos E. Politou MC, et al. Int J Cancer. 2006 Oct 1;119(7):1728-31. doi: 10.1002/ijc.22033. Int J Cancer. 2006. PMID: 16646053

10

Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index.

Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J, Viniou N, Yataganas X, Goldman JM, Rahemtulla A. Terpos E, et al. Among authors: politou m. Blood. 2003 Aug 1;102(3):1064-9. doi: 10.1182/blood-2003-02-0380. Epub 2003 Apr 10. Blood. 2003. PMID: 12689925 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

142 results

Search Page

Filters